Dudediligence.

UroGen Pharma Ltd

URGNNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$25.2MSep ’24$24.6MDec ’24$20.3MMar ’25$24.2MJun ’25$27.5MSep ’25$37.8MDec ’25$51.0MMar ’26$72.5MJun ’26
Net income, by quarter
−$23.7MSep ’24−$37.5MDec ’24−$43.8MMar ’25−$49.9MJun ’25−$33.3MSep ’25−$26.4MDec ’25−$23.6MMar ’26−$14.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$48.0M$64.4M$82.7M$90.4M$109.8M
Gross profit$42.9M$56.7M$73.4M$81.5M$97.3M
Operating income−$92.3M−$79.0M−$65.5M−$96.8M−$124.9M
Net income−$110.8M−$109.8M−$102.2M−$126.9M−$153.5M
Operating cash flow−$84.9M−$87.6M−$76.4M−$96.8M−$162.4M
Free cash flow−$85.6M−$87.8M−$76.6M−$97.1M−$162.7M
Cash$44.4M$55.4M$95.0M$172.0M$110.7M
Debt$0.00$97.5M$98.6M$121.7M$122.2M
Shares outstanding22.5M23.1M32.5M42.2M48.4M